ATE349446T1 - Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel - Google Patents

Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel

Info

Publication number
ATE349446T1
ATE349446T1 AT02728893T AT02728893T ATE349446T1 AT E349446 T1 ATE349446 T1 AT E349446T1 AT 02728893 T AT02728893 T AT 02728893T AT 02728893 T AT02728893 T AT 02728893T AT E349446 T1 ATE349446 T1 AT E349446T1
Authority
AT
Austria
Prior art keywords
diagnostic imaging
imaging agents
amyloid plaque
aggregation inhibitors
plaque aggregation
Prior art date
Application number
AT02728893T
Other languages
English (en)
Inventor
Hank F Kung
Mei-Ping Kung
Zhi-Ping Zhuang
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE349446T1 publication Critical patent/ATE349446T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic System
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
AT02728893T 2001-04-23 2002-04-23 Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel ATE349446T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28528201P 2001-04-23 2001-04-23

Publications (1)

Publication Number Publication Date
ATE349446T1 true ATE349446T1 (de) 2007-01-15

Family

ID=23093574

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02728893T ATE349446T1 (de) 2001-04-23 2002-04-23 Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel

Country Status (12)

Country Link
US (5) US6696039B2 (de)
EP (1) EP1381604B1 (de)
JP (1) JP4317955B2 (de)
KR (1) KR20040058111A (de)
CN (1) CN100422180C (de)
AT (1) ATE349446T1 (de)
AU (1) AU2002258915B2 (de)
CA (1) CA2444214A1 (de)
DE (1) DE60217090T2 (de)
ES (1) ES2274973T3 (de)
TW (1) TWI245764B (de)
WO (1) WO2002085903A2 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544511B2 (en) * 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
GB0018473D0 (en) * 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
HU230375B1 (hu) 2000-08-24 2016-03-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Tioflavin-származékok és alkalmazásuk az Alzheimer-kór diagnózisában és kezelésében
CN100422180C (zh) * 2001-04-23 2008-10-01 宾夕法尼亚州大学理事会 淀粉样斑块聚集抑制剂和诊断成像剂
CA2474411A1 (en) * 2002-02-13 2003-08-21 Amersham Plc Benzothiazole derivatives for in vivo imaging of amyloid plaques
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
WO2004053071A2 (en) * 2002-12-09 2004-06-24 Judith Kelleher-Andersson Method for discovering neurogenic agents
US20040204344A1 (en) * 2003-01-22 2004-10-14 Xudong Huang Amyloid-binding, metal-chelating agents
AU2004221897B2 (en) * 2003-03-14 2010-11-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Benzothiazole derivative compounds, compositions and uses
CA2438032C (en) * 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
GB0307855D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
EP1631561B1 (de) 2003-05-07 2010-08-18 General Electric Company Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid
US8236282B2 (en) 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
US20050049487A1 (en) * 2003-08-26 2005-03-03 Johnson Bruce Fletcher Compounds and kits for preparing imaging agents and methods of imaging
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
EP1732864B1 (de) * 2004-03-18 2013-12-25 Suntory Holdings Limited Radioaktiv markiertes 3-[3-(benzoylamido)benzyloxy]asparaginsäurederivat und verfahren zu dessen herstellung
CA2587248C (en) * 2004-07-02 2014-01-07 William E. Klunk Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies
EP1768709A1 (de) * 2004-07-02 2007-04-04 University of Pittsburgh Verfahren zur diagnose von prodromalen formen von erkrankungen im zusammenhang mit amyloid-ablagerung
WO2006026184A2 (en) * 2004-08-20 2006-03-09 Washington University Blood brain barrier permeation peptides
KR101505347B1 (ko) 2004-11-17 2015-03-23 뉴럴스템, 인크. 신경퇴행성 증상의 치료를 위한 인간 신경 세포의 이식
EP1893245A4 (de) * 2005-06-24 2009-06-24 Univ Pennsylvania Radioaktiv markierte pegylierung von liganden zur verwendung als kontrastmittel
WO2007011834A2 (en) * 2005-07-15 2007-01-25 The Regents Of The University Of California Compounds and method for the diagnosis and treatment of amyloid associated diseases
EP1928237A4 (de) 2005-09-02 2011-03-09 Abbott Lab Neue heterocyclen auf imidazo-basis
WO2007033080A2 (en) * 2005-09-12 2007-03-22 Emory University Alzheimer's disease imaging agents
ATE533485T1 (de) † 2005-10-31 2011-12-15 Merck Sharp & Dohme Cetp-inhibitoren
EP1956013B1 (de) 2005-11-30 2016-04-13 Fujifilm RI Pharma Co., Ltd. Diagnostikum und heilmittel für eine durch amyloidaggregation und/oder ablagerung verursachte krankheit
WO2007069565A1 (ja) * 2005-12-12 2007-06-21 Ono Pharmaceutical Co., Ltd. 二環式複素環化合物
WO2007078335A2 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TW200803903A (en) 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
WO2008118122A2 (en) * 2006-05-08 2008-10-02 Molecular Neuroimaging, Llc Compounds and amyloid probes thereof for therapeutic and imaging uses
JP5238496B2 (ja) 2006-05-19 2013-07-17 日本メジフィジックス株式会社 新規アミロイド親和性化合物
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
AU2007261985B2 (en) 2006-06-21 2012-04-19 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
EP2080526A4 (de) * 2006-11-09 2012-11-07 Nihon Mediphysics Co Ltd Radioaktives diagnostisches abbildungsagens
EP2098523A4 (de) * 2006-11-17 2011-09-21 Nihon Mediphysics Co Ltd Neue, amyloid-affine verbindungen
KR20090083414A (ko) 2006-11-30 2009-08-03 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
KR20090101469A (ko) * 2007-01-22 2009-09-28 아스트라제네카 아베 신규 헤테로아릴 치환된 이미다조〔１，２­ａ〕피리딘 유도체
US8343459B2 (en) 2007-02-13 2013-01-01 Nihon Medi-Physics Co., Ltd. Method for production of radiation diagnostic imaging agent
EP1964840A1 (de) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridine und deren pharmazeutische Verwendung
JP2010520275A (ja) * 2007-03-06 2010-06-10 アストラゼネカ・アクチエボラーグ 新規な２−ヘテロアリール置換インドール６９５
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
FR2913886B1 (fr) * 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
WO2008134618A2 (en) * 2007-04-27 2008-11-06 The General Hospital Corporation Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders
TW200918102A (en) 2007-10-24 2009-05-01 Nihon Mediphysics Co Ltd Novel compound having affinity for amyloid
TW200918101A (en) 2007-10-26 2009-05-01 Nihon Mediphysics Co Ltd Novel compound having affinity for amyloid
JPWO2009057577A1 (ja) * 2007-10-30 2011-03-10 日本メジフィジックス株式会社 新規アミロイド親和性化合物の使用及び製造方法
KR20100089858A (ko) * 2007-10-30 2010-08-12 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법
US20100249419A1 (en) * 2007-10-30 2010-09-30 Nihon Medi-Physics Co., Ltd. Utilization of novel compounds with amyloid affinity and method of producing the same
CA2704168A1 (en) * 2007-10-30 2009-05-07 Nihon Medi-Physics Co., Ltd. Use of novel compound having affinity for amyloid, and process for production of the same
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
US20110046378A1 (en) 2008-02-14 2011-02-24 Siemens Medical Solutions Usa, Inc. Novel Imaging Agents for Detecting Neurological Dysfunction
US20100331676A1 (en) * 2008-02-27 2010-12-30 Avid Radiopharmaceuticals, Inc. Gamma probe detection of amyloid plaque using radiolabeled a-beta binding compounds
CA2978149C (en) 2008-03-21 2019-02-12 The General Hospital Corporation Inositol derivatives for the detection and treatment of alzheimer's disease and related disorders
US8557222B2 (en) * 2008-04-04 2013-10-15 Avid Radiopharmaceuticals, Inc. Radiopharmaceutical imaging of neurodegenerative diseases
US8409419B2 (en) 2008-05-21 2013-04-02 Paul R. Kruesi Conversion of carbon to hydrocarbons
WO2009146388A1 (en) 2008-05-28 2009-12-03 The Trustees Of Columbia University In The City Of New York Voxel-based methods for assessing subjects using positron emission tomography
AU2009260519A1 (en) * 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
AU2009260526A1 (en) * 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted indoles
AU2009253046A1 (en) * 2008-05-30 2009-12-03 Foster Wheeler Energia Oy Method of and system for generating power by oxyfuel combustion
KR20110046503A (ko) 2008-07-24 2011-05-04 지멘스 메디컬 솔루션즈 유에스에이, 인크. Ａｄ 병인을 확인하기에 유용한 영상화제
WO2010039815A1 (en) * 2008-09-30 2010-04-08 Case Western Reserve University Molecular probes for imaging of myelin
JP2012508889A (ja) * 2008-11-13 2012-04-12 アビッド レディオファーマシューティカルズ、インク． 神経変性疾患の検出と診断のためのヒストグラムに基づいた分析方法
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2218464A1 (de) * 2009-02-11 2010-08-18 Technische Universität München Verbindungen zur nichtinvasiven Messung von Aggregaten von Amyloidpeptiden
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
EP2411057B1 (de) * 2009-03-23 2020-05-06 Eli Lilly and Company Bildgebungsmittel zum nachweis von neurologischen erkrankungen
CU23844B1 (es) 2009-04-17 2012-10-15 Ct De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
US8476449B2 (en) 2010-03-01 2013-07-02 Nihon Medi-Physics Co., Ltd. Radioactive iodine labeled organic compound or salt thereof
KR101765980B1 (ko) 2010-07-28 2017-08-07 뉴럴스템, 인크. 신경퇴행성 질환 및/또는 장애의 치료 및/또는 역전 방법
WO2012051170A2 (en) 2010-10-12 2012-04-19 Mayo Foundation For Medical Education And Research Imaging of meningiomas using phingylbenzothiazole, stilbene, or biphenylalkyne derivatives
JP2013542254A (ja) * 2010-11-16 2013-11-21 ジーイー・ヘルスケア・リミテッド タウ病理のイメージングプローブとしての複素環式化合物
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
CA2836872A1 (en) 2011-05-20 2012-11-29 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
JP5167436B2 (ja) 2011-06-24 2013-03-21 日本メジフィジックス株式会社 新規アミロイド親和性化合物
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
US20140335019A1 (en) * 2011-12-02 2014-11-13 The Regents Of The University Of Michigan Compositions and methods for the treatment and analysis of neurological disorders
US20150157744A1 (en) 2012-06-27 2015-06-11 Geoffrey B. Johnson Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
CN103073520B (zh) * 2012-12-24 2014-10-08 湖南大学 一种合成2-苯基苯并噻唑及其衍生物的方法
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
WO2014124334A2 (en) 2013-02-08 2014-08-14 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
RU2015147450A (ru) 2013-04-29 2017-06-05 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ 2-ФЕНИЛ ИЛИ 2-ГЕТЕРОАРИЛ ИМИДАЗОЛ[1,2-a]ПИРИДИНА
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
KR101770532B1 (ko) 2013-09-26 2017-08-22 에프. 호프만-라 로슈 아게 이미징 수단으로서의 이미다조[1,2-a]피리딘-7-아민
JP2016534063A (ja) 2013-10-22 2016-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリン誘導体ならびに関連するイメージングおよび治療方法
EP3209306B1 (de) 2014-10-20 2024-04-24 Neuralstem, Inc. Stabile neurale stammzellen mit einem exogenen polynukleotid zur codierung eines wachstumsfaktors und verfahren zur verwendung davon
EP3384960B1 (de) * 2015-12-30 2019-06-05 Neuboron Medtech Ltd. Neutroneneinfangtherapiesystem zur beseitigung von amyloid-beta-protein
WO2017114317A1 (zh) * 2015-12-30 2017-07-06 南京中硼联康医疗科技有限公司 和β淀粉样蛋白特异性结合的化合物
CN109922800B (zh) 2016-08-31 2023-06-13 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
AU2017423862A1 (en) 2017-07-20 2020-02-06 Aztherapies, Inc. Powdered formulations of cromolyn sodium and ibuprofen
JP6831802B2 (ja) * 2018-01-12 2021-02-17 上海富吉医療器械有限公司Ｓｈａｎｇｈａｉ Ｃｈａｒｔｗｅｌｌ Ｍｅｄｉｃａｌ Ｉｎｓｔｒｕｍｅｎｔ Ｃｏ．， Ｌｔｄ． 放射性核種標識化合物及びこれを含有するイメージング剤
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
KR102240400B1 (ko) * 2020-11-19 2021-04-15 한국원자력연구원 베타-아밀로이드 검출용 수용성 화합물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317949D0 (en) 1993-08-28 1993-10-13 Stevens Malcolm F G Benzothiazole compounds
US5552415A (en) 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
US6417178B1 (en) 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US6054114A (en) * 1996-05-08 2000-04-25 Massachusetts Institute Of Technology Organometallic ligands for the localization and quantification of amyloid in vivo and in vitro
WO1998017267A1 (en) 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5869500A (en) 1996-12-13 1999-02-09 Hoffmann-La Roche Inc. Pyridone compounds useful in treating Alzheimer's disease
US6037473A (en) 1997-11-13 2000-03-14 Haarmann & Reimer Gmbh Use of substituted benzazoles as UV absorbers, new benzazoles and processes for their preparation
CN100422180C (zh) 2001-04-23 2008-10-01 宾夕法尼亚州大学理事会 淀粉样斑块聚集抑制剂和诊断成像剂

Also Published As

Publication number Publication date
DE60217090T2 (de) 2007-07-12
KR20040058111A (ko) 2004-07-03
TWI245764B (en) 2005-12-21
US6946116B2 (en) 2005-09-20
EP1381604B1 (de) 2006-12-27
JP4317955B2 (ja) 2009-08-19
USRE44338E1 (en) 2013-07-02
AU2002258915B2 (en) 2007-11-15
WO2002085903A2 (en) 2002-10-31
EP1381604A2 (de) 2004-01-21
US20030059369A1 (en) 2003-03-27
CN100422180C (zh) 2008-10-01
US7425318B2 (en) 2008-09-16
US20060051293A1 (en) 2006-03-09
US6696039B2 (en) 2004-02-24
CN1620454A (zh) 2005-05-25
JP2005512945A (ja) 2005-05-12
US20040131545A1 (en) 2004-07-08
CA2444214A1 (en) 2002-10-31
DE60217090D1 (de) 2007-02-08
USRE44354E1 (en) 2013-07-09
ES2274973T3 (es) 2007-06-01
WO2002085903A3 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
ATE349446T1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
HK1110313A1 (en) Stilbene derivatives and their use for binding and imaging amyloid plaques
MX2007007380A (es) Derivados de estilbeno y su uso para estudios de union y por imagenes de placas amiloides.
WO2007033080A3 (en) Alzheimer's disease imaging agents
WO2006078384A3 (en) Stilbene derivatives and their use
CY1107383T1 (el) Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
MXPA04008068A (es) Metodo para administrar moleculas de glp-1.
ATE539060T1 (de) Styrylpyridinderivate und ihre verwendung zur bindung und abbildung von amyloider plaque
DK1472541T3 (da) Afbildningsmidler og metoder til at afbilde NAALADase og PSMA
ATE439868T1 (de) Targetingmittel für molekulare bilderzeugung
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
EE04911B1 (et) Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
HUP0204074A2 (hu) Abéta peptidet kiválasztó humanizált ellenanyagok
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
DK1553985T3 (da) Biphenyler som billeddannelsesmiddel i forbindelse med Alzheimers sygdom
ATE433331T1 (de) Kontrastmittel für die magnetresonanztomographie und entsprechende verfahren
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1381604

Country of ref document: EP

REN Ceased due to non-payment of the annual fee